Literature DB >> 24944078

Androgen receptor enhances cell adhesion and decreases cell migration via modulating β1-integrin-AKT signaling in hepatocellular carcinoma cells.

Wen-Lung Ma1, Long-Bin Jeng2, Hsueh-Chou Lai2, Pei-Yin Liao3, Chawnshang Chang4.   

Abstract

The androgen receptor (AR) has been shown to promote the initiation and development of hepatocellular carcinoma (HCC) during the early stage of the disease process and to suppress HCC cell invasion during the later stages of the disease. The mechanisms governing these dual yet opposite roles have yet to be elucidated. Using carcinogen-induced HCC in vivo mouse models and the in vitro human HCC cell line SKhep1, we found that knockout of AR in primary HCC cells led to a decrease in HCC cell focal adhesion capacity compared to cells from wildtype mice. Similar results were obtained after adding functional AR into human HCC SKhep1 cells. Further analysis revealed that the role AR plays in adhesion of HCC cells is governed, at least in part, by its ability to up-regulate β1-integrin and activate the PI3K/AKT pathway. We also found that AR-β1-integrin-mediated cell adhesion suppresses cell migration. Those findings indicate that the AR-β1-integrin-PI3K/AKT signaling pathway might play a role in the bimodal function of AR on cell adhesion and migration at the cellular level.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adhesion; Androgen receptor; Hepatocellular carcinoma; Migration

Mesh:

Substances:

Year:  2014        PMID: 24944078     DOI: 10.1016/j.canlet.2014.05.017

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  26 in total

1.  Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.

Authors:  Liang Shi; Hui Lin; Gonghui Li; Ren-An Jin; Junjie Xu; Yin Sun; Wen-Lung Ma; Shuyuan Yeh; Xiujun Cai; Chawnshang Chang
Journal:  Mol Cancer Ther       Date:  2016-03-03       Impact factor: 6.261

2.  Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.

Authors:  Liang Shi; Hui Lin; Gonghui Li; Yin Sun; Jiliang Shen; Junjie Xu; Changyi Lin; Shuyuan Yeh; Xiujun Cai; Chawnshang Chang
Journal:  Cancer Lett       Date:  2016-01-19       Impact factor: 8.679

3.  Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers.

Authors:  Tuhina Mazumdar; Banibrata Sen; Yifan Wang; Shaohua Peng; Courtney Nicholas; Bonnie S Glisson; Jeffrey N Myers; Faye M Johnson
Journal:  Anticancer Drugs       Date:  2015-09       Impact factor: 2.248

4.  TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy.

Authors:  Michael R McLoughlin; David J Orlicky; Justin R Prigge; Pushya Krishna; Emily A Talago; Ian R Cavigli; Sofi Eriksson; Colin G Miller; Jean A Kundert; Volkan I Sayin; Rachel A Sabol; Joshua Heinemann; Luke O Brandenberger; Sonya V Iverson; Brian Bothner; Thales Papagiannakopoulos; Colin T Shearn; Elias S J Arnér; Edward E Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-16       Impact factor: 12.779

5.  Marine bromophenol bis (2,3-dibromo-4,5-dihydroxy-phenyl)-methane inhibits the proliferation, migration, and invasion of hepatocellular carcinoma cells via modulating β1-integrin/FAK signaling.

Authors:  Ning Wu; Jiao Luo; Bo Jiang; Lijun Wang; Shuaiyu Wang; Changhui Wang; Changqing Fu; Jian Li; Dayong Shi
Journal:  Mar Drugs       Date:  2015-02-13       Impact factor: 5.118

6.  Reduced dosing and liability in methadone maintenance treatment by targeting oestrogen signal for morphine addiction.

Authors:  Yao-Chang Chiang; Ruey-Yun Wang; Chieh-Liang Huang; Shue-Hwa Chen; Wen-Jing Ho; Hsien-Yuan Lane; Ing-Kang Ho; Hwei-Ting Yang; Wen-Lung Ma
Journal:  J Cell Mol Med       Date:  2017-07-12       Impact factor: 5.310

7.  HYD-PEP06 suppresses hepatocellular carcinoma metastasis, epithelial-mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K/AKT and WNT/β-catenin signaling activation.

Authors:  Wei Tian; Jiatong Li; Zhuo Wang; Tong Zhang; Ying Han; Yanyan Liu; Wenfeng Chu; Yu Liu; Baofeng Yang
Journal:  Acta Pharm Sin B       Date:  2021-04-02       Impact factor: 11.413

Review 8.  The androgen receptor as an emerging target in hepatocellular carcinoma.

Authors:  Tatsuo Kanda; Osamu Yokosuka
Journal:  J Hepatocell Carcinoma       Date:  2015-06-26

9.  Long noncoding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3.

Authors:  Jing Jia; Feng Li; Xiao-Shuang Tang; Shan Xu; Yang Gao; Qi Shi; Wenhuan Guo; Xinyang Wang; Dalin He; Peng Guo
Journal:  Oncotarget       Date:  2016-06-21

10.  Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells.

Authors:  Hsueh-Chou Lai; Chun-Chieh Yeh; Long-Bin Jeng; Shang-Fen Huang; Pei-Ying Liao; Fu-Ju Lei; Wei-Chun Cheng; Cheng-Lung Hsu; Xiujun Cai; Chawnshang Chang; Wen-Lung Ma
Journal:  Oncotarget       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.